Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 4Solid Tumors 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Sarcoma 1Recurrence 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Leukemia 1Carcinoma 1Bone Marrow Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

romidepsin 12Cyclophosphamide 11Vincristine 9Rituximab 9Etoposide 9Lenalidomide 8Doxorubicin 8Brentuximab Vedotin 8fludarabine 6Prednisone 6Peripheral Blood Stem Cell Transplantation 6Melphalan 6Depsipeptides 6fludarabine phosphate 5Mycophenolic Acid 5Lactones 5Gemcitabine 5Cytarabine 5Bendamustine Hydrochloride 5Antilymphocyte Serum 5Whole-Body Irradiation 4Tacrolimus 4Sirolimus 4Methotrexate 4MLN 8237 4Carmustine 4Bortezomib 410-propargyl-10-deazaaminopterin 4thymoglobulin 3duvelisib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell × darinaparsin × Clear all
NCT00421213 2012-07-19

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Alaunos Therapeutics

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Bone Marrow Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡